mAbxience | Clinical experience: rigorous credentials
Two clinical trials for two of our products (rituximab and bevacizumab) have been completed in a total of 17 countries and 75 research centers*. These trials were conducted in patients with non-Hodgkin lymphoma (rituximab) and metastatic colorectal cancer (bevacizumab).
- Rituximab: Worldwide development of a clinical trial to determine the Response Rate (RR) obtained with Rituximab Biosimilar combined with CHOP1 in patients with Diffuse Large B-Cell Lymphoma (DLBCL).
1CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone
- Bevacizumab: Worldwide development of a clinical trial to compare the Pharmacokinetic (PK) profile of Bevacizumab Biosimilar and the Reference Medical Product (RMP) administered in combination with FOLFOX2 or FOLFIRI3.
2FOLFOX: 5-fluorouracil/leucovorin combined with oxaliplatin
3FOLFIRI: 5-fluorouracil/leucovorin combined with irinotecan